Page last updated: 2024-11-05

1,4-dioxane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4-Dioxane is a heterocyclic organic compound with the formula (CH2CH2O)2. It is a colorless liquid with a faint, ethereal odor. 1,4-Dioxane is a common solvent used in industrial and laboratory settings. It is also found as a contaminant in some consumer products, such as cosmetics and detergents. The compound is synthesized by the acid-catalyzed dehydration of diethylene glycol. 1,4-Dioxane is a suspected human carcinogen and is also a skin and eye irritant. It is studied due to its potential health risks and its prevalence in various industrial processes. 1,4-Dioxane is also an important reagent in organic synthesis and is used as a stabilizer for certain types of polymers.'

1,4-dioxane: dehydrating agent; polar solvent miscible both with water & most organic solvents [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dioxane : Any member of the class of dioxanes that is a cyclohexane in which two carbon atoms are replaced by oxygen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1,4-dioxane : A dioxane with oxygen atoms at positions 1 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID31275
CHEMBL ID453716
CHEBI ID47032
MeSH IDM0084336

Synonyms (142)

Synonym
BIDD:ER0341
tetrahydro-p-dioxin
dioxane-1,4
wln: t6o dotj
tetrahydro-1,4-dioxin
diokan
glycol ethylene ether
dioxanne
nsc8728
diethylene ether
dioxaan-1,4
diossano-1,4
dioxan
123-91-1
1,4-dioxane
dioxan-1,4
dioxane
dioksan
diethylene dioxide
nsc-8728
nci-c03689
di(ethylene oxide)
p-dioxan
dioxyethylene ether
1,4-dioxan
1,4-diethylene dioxide
p-dioxane
inchi=1/c4h8o2/c1-2-6-4-3-5-1/h1-4h
rcra waste no. u108
1,4-diethylenedioxide
brn 0102551
einecs 204-661-8
dioxan-1,4 [german]
p-dioxan [czech]
un 1165
dioxaan-1,4 [dutch]
dioxane, technical grade
1,4-dioxanne [french]
ccris 269
dioxanne [french]
diossano-1,4 [italian]
rcra waste number u108
un1165
dioksan [polish]
ne 220
1,4-diethyleneoxide
p-dioxin, tetrahydro-
hsdb 81
glycolethylenether
nsc 8728
ai3-01055
para-dioxane
1,4-dioxane, aldrasorb(tm), 99.8%
DB03316
CHEBI:47032 ,
1,4-dioxacyclohexane
tetrahydro-para-dioxin
1-4 dioxane
1,4-dioxane, puriss., absolute, over molecular sieve (h2o <=0.01%), >=99.5% (gc)
1,4-dioxane, histological grade, >=99%
1,4-dioxane, anhydrous, 99.8%
D0860
CHEMBL453716
AKOS000120203
NCGC00248888-01
dtxcid00533
NCGC00258524-01
cas-123-91-1
tox21_200971
dtxsid4020533 ,
[1,4]dioxane
5-19-01-00016 (beilstein handbook reference)
ec 204-661-8
unii-j8a3s10o7s
j8a3s10o7s ,
1,4-dioxanne
dioxane [un1165] [flammable liquid]
FT-0606896
FT-0606897
1,4-dioxane [usp-rs]
dioxan [mart.]
1,4-dioxane [hsdb]
dioxane [mi]
1,4-dioxane [iarc]
STL264191
BRD-K42978307-001-01-0
dioxane 1.4
1,4,-dioxane
1,4- dioxane
1,4 -dioxan
[1,4]-dioxane
1,4dioxan
1-4-dioxane
1.4-dioxane
1,4dioxane
1,-4-dioxane
1,4-di-oxane
1 ,4-dioxan
paradioxane
1,4 dioxan
1,4 dioxane
1 ,4-dioxane
1, 4-dioxane
1, 4 dioxane
1,4 -dioxane
1,4-dioxin, tetrahydro-
glycol ethylene ether 8
mfcd00006571
1,4-dioxane, hplc grade
J-523874
J-004995
p-doxane
1,4-dioxane, analytical standard
1,4-dioxane, anhydrous
1,4-dioxane, for hplc
1,4-dioxane, for hplc, >=99.5%
1,4-dioxane, puriss. p.a., dried, >=99.5% (gc), <=0.005% water
1,4-dioxane, spectrophotometric grade, >=99%
1,4-dioxane, hplc grade, 99.9%
1,4-dioxane, saj first grade
1,4-dioxane, jis special grade, >=99.0%
1,4-dioxane, puriss. p.a., acs reagent, reag. iso, reag. ph. eur., >=99.5% (gc)
residual solvent class 2 - 1,4-dioxane, united states pharmacopeia (usp) reference standard
1,4-dioxane, acs reagent, >=99.0%
1,4-dioxane, >=99.5%, for titration in non-aqueous medium
1,4-dioxane, reagentplus(r), >=99%
1,4-dioxane, anhydrous, zero2(tm), 99.8%
1,4-dioxane, p.a., 99%
1,4-dioxane, for hplc, >=99.7%
1,4-dioxane, pharmaceutical secondary standard; certified reference material
1,4-dioxane, ar, >=99.5%
1,4-dioxane, lr, >=99%
1,4-dioxane, uv hplc spectroscopic, 99.9%
1,4-dioxane 1000 microg/ml in methanol
1,4-dioxane, acs grade
BCP16201
39449-24-6
54841-74-6
1,4-dioxane 1000 microg/ml in acetonitrile
Q161532
AMY33329
28552-22-9

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" A LOAEL (lowest observed adverse effect level) was determined at 50 ppm for the nasal endpoint of general chronic toxicity."( Two-year inhalation study of carcinogenicity and chronic toxicity of 1,4-dioxane in male rats.
Arito, H; Fukushima, S; Ikawa, N; Kano, H; Kasai, T; Nagano, K; Nagashima, H; Nishizawa, T; Sasaki, T; Umeda, Y, 2009
)
0.59

Pharmacokinetics

ExcerptReferenceRelevance
" In order to determine more accurately the likely human response following lifetime exposure to dioxane, a physiologically-based pharmacokinetic (PB-PK) model was developed."( Cancer risk assessment for dioxane based upon a physiologically-based pharmacokinetic approach.
Leung, HW; Paustenbach, DJ, 1990
)
0.28
"A six compartment physiologically based pharmacokinetic (PB-PK) model was developed to describe the disposition of diethylene-1,4-dioxide (dioxane) and its principal metabolite beta-hydroxyethoxyacetic acid in rats, mice, and humans."( Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane.
Andersen, ME; Gargas, ML; McCroskey, PS; Park, CN; Reitz, RH, 1990
)
0.5
" However, because biotransformation and excretion of many chemicals are capacity-limited processes, extrapolation of toxicity to lower doses, without adequate pharmacokinetic information at those lower dose levels may result in overestimation of predicted toxicity."( Sources of uncertainty in pharmacokinetic prediction.
Braun, WH; Waechter, JM, 1983
)
0.27
" Two physiologically based pharmacokinetic (PBPK) models of 1,4-dioxane and its major metabolite, hydroxyethoxyacetic acid (HEAA), were published in 1990."( Physiologically based pharmacokinetic modeling of 1,4-Dioxane in rats, mice, and humans.
Clarkson, J; Corley, RA; Gargas, ML; Locey, BJ; Poet, TS; Sager, S; Sweeney, LM; Thrall, KD; Weber, TJ, 2008
)
0.84
" The ASD/CsA was characterized in terms of morphology, particle size distribution, crystallinity, dissolution behavior, physicochemical stability, and pharmacokinetic behavior in rats."( Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization.
Morinaga, T; Moritani, T; Onoue, S; Sato, H; Seto, Y; Suzuki, H, 2017
)
0.46

Compound-Compound Interactions

ExcerptReferenceRelevance
"Ozonation combined with electrolysis (ozone-electrolysis) is a new advanced oxidation process for water treatment."( Ozonation combined with electrolysis of 1,4-dioxane using a two-compartment electrolytic flow cell with solid electrolyte.
Abe, M; Asano, M; Kishimoto, N; Nakagawa, T; Ono, Y; Yamada, M, 2008
)
0.61

Bioavailability

ExcerptReferenceRelevance
" After oral administration of CsA samples (10mg-CsA/kg) in rats, the ASD/CsA showed a high and sustained plasma concentration of CsA as evidenced by a 18-fold increase in the oral bioavailability of CsA compared with amorphous CsA."( Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization.
Morinaga, T; Moritani, T; Onoue, S; Sato, H; Seto, Y; Suzuki, H, 2017
)
0.46

Dosage Studied

Adding antibiotics (sulfamethoxazole and ciprofloxacin), that temporarily inhibited the nitrification process during the dosing period, showed a minor effect in 1,4-dioxane removal (6-8% decline, p < 0.0). We estimated the point of departure of the mutagenicity and carcinogenicity of 1,3-Dioxane using the Benchmark dose approach.

ExcerptRelevanceReference
" On oral dosing (10 mg/kg) to rats and dogs, 110 showed significant TXRA activity [concentration ratio > 64 (rat, 3 h) and > 59 +/- 11."( A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors.
Ackerley, N; Brewster, AG; Brown, GR; Clarke, DS; Foubister, AJ; Griffin, SJ; Hudson, JA; Smithers, MJ; Whittamore, PR, 1995
)
0.29
" However, in a current series of trials with TdR, it showed equivocal responses 24 or 48 hr following treatment with 2000 mg/kg in time-course experiments, and positive responses 24 hr following 1000, 1500 and 2000 mg/kg in dose-response experiments."( Repeat-assessment of 1,4-dioxane in a rat-hepatocyte replicative DNA synthesis (RDS) test: evidence for stimulus of hepatocyte proliferation.
Miyagawa, M; Shirotori, T; Tsuchitani, M; Yoshikawa, K, 1999
)
0.62
"The objective of this work is to study the interaction of a copolymer, poly methyl vinyl ether/maleic anhydride (PMV/MA) used in pharmaceutical dosage form and a phospholipid L-alpha-dimiristoyl phosphatidylcholine (DMPC) with the aim of developing a bioadhesive system."( Interaction of poly methyl vinyl ether/maleic anhydride-dimiristoyl phosphatidylcholine: a model bioadhesion study.
Ballesteros, MP; Castro, RM; Lastres, JL; Nuñez, JL, 2000
)
0.31
" In contrast, dosing with pozzolan decomposed up to 98."( Decomposition of 1,4-dioxane by advanced oxidation and biochemical process.
Kim, CG; Lee, BR; Seo, HJ, 2006
)
0.67
" Increases in plasma levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and a decrease in plasma glucose were noted primarily in the rats and mice dosed 25,000 ppm."( Thirteen-week oral toxicity of 1,4-dioxane in rats and mice.
Aiso, S; Fukushima, S; Kano, H; Nagano, K; Ohbayashi, H; Saito, M; Senoh, H; Umeda, Y; Yamazaki, K, 2008
)
0.63
" Because our data indicate that 1,4-dioxane is a genotoxic carcinogen, we estimated the point of departure of the mutagenicity and carcinogenicity of 1,4-dioxane using the no-observed effect-level approach and the Benchmark dose approach to characterize its dose-response relationship at low doses."( In vivo positive mutagenicity of 1,4-dioxane and quantitative analysis of its mutagenicity and carcinogenicity in rats.
Fujioka, M; Fukushima, S; Gi, M; Kakehashi, A; Masumura, K; Matsumoto, M; Nohmi, T; Okuno, T; Omori, M; Wanibuchi, H, 2018
)
1.05
" For the liver micronucleus test, we performed the juvenile animal method and two methods using partial hepatectomy (PH), dosing before PH or dosing after PH."( In vivo genotoxicity of 1,4-dioxane evaluated by liver and bone marrow micronucleus tests and Pig-a assay in rats.
Hattori, C; Itoh, S, 2019
)
0.82
" Adding antibiotics (sulfamethoxazole and ciprofloxacin), that temporarily inhibited the nitrification process during the dosing period, showed a minor effect in 1,4-dioxane removal (6-8% decline, p < 0."( 1,4-Dioxane removal in nitrifying sand filters treating domestic wastewater: Influence of water matrix and microbial inhibitors.
Brownawell, BJ; Clyde, PM; Lee, CS; Mao, X; Venkatesan, AK; Wang, M, 2023
)
2.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
non-polar solventnull
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
NMR chemical shift reference compoundAny compound that produces a peak used to reference an NMR spectrum during data pre-processing.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dioxaneAny member of the class of dioxanes that is a cyclohexane in which two carbon atoms are replaced by oxygen atoms.
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
mixed acid fermentation3276

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.73580.003041.611522,387.1992AID1159552; AID1159555
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID343683Octanol-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID343684Alkane-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (663)

TimeframeStudies, This Drug (%)All Drugs %
pre-199057 (8.60)18.7374
1990's78 (11.76)18.2507
2000's195 (29.41)29.6817
2010's253 (38.16)24.3611
2020's80 (12.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.16 (24.57)
Research Supply Index6.55 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index136.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.29%)5.53%
Reviews18 (2.59%)6.00%
Case Studies2 (0.29%)4.05%
Observational0 (0.00%)0.25%
Other673 (96.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]